Cargando…

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

BACKGROUND: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Havrdová, Eva, Arnold, Douglas L, Bar-Or, Amit, Comi, Giancarlo, Hartung, Hans-Peter, Kappos, Ludwig, Lublin, Fred, Selmaj, Krzysztof, Traboulsee, Anthony, Belachew, Shibeshih, Bennett, Iain, Buffels, Regine, Garren, Hideki, Han, Jian, Julian, Laura, Napieralski, Julie, Hauser, Stephen L, Giovannoni, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858626/ https://www.ncbi.nlm.nih.gov/pubmed/29568544 http://dx.doi.org/10.1177/2055217318760642

Ejemplares similares

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
por: Wiendl, Heinz, et al.
Publicado: (2016)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
por: Arnold, Douglas L, et al.
Publicado: (2022)

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
por: Fox, Edward J, et al.
Publicado: (2018)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

NEDA—NEutron Detector Array
por: Valiente-Dobón, J J, et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
por: Cree, Bruce AC, et al.
Publicado: (2022)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis
por: Rotstein, Dalia, et al.
Publicado: (2022)

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
por: Chang, Ih, et al.
Publicado: (2022)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
por: Gibiansky, Ekaterina, et al.
Publicado: (2020)

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
por: Cohan, Stanley, et al.
Publicado: (2017)

Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
por: Garcia, Alexandra, et al.
Publicado: (2023)

Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a
por: MacMillan, Erin L, et al.
Publicado: (2019)

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
por: Hartung, H-P, et al.
Publicado: (2020)

Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment
por: Smets, I., et al.
Publicado: (2021)

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Erratum zu: Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS
por: Hartung, Hans-Peter
Publicado: (2020)

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
por: Elliott, Colm, et al.
Publicado: (2019)

The cubist epoch
por: Cooper, Douglas, 1911-1984
Publicado: (1970)

The Psychology of Epochs
Publicado: (1852)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l6jh7tlfaij98bo6js25opa3hp